Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y5Q5

UPID:
CORIN_HUMAN

ALTERNATIVE NAMES:
Corin; Heart-specific serine proteinase ATC2; Pro-ANP-converting enzyme; Transmembrane protease serine 10

ALTERNATIVE UPACC:
Q9Y5Q5; B0ZBE3; Q2TBD2; Q4W5E5; Q4W5G6; Q9UHY2

BACKGROUND:
Atrial natriuretic peptide-converting enzyme, or Corin, plays a critical role in cardiovascular homeostasis by converting propeptides NPPA and NPPB into their active forms, ANP and BNP. These hormones are essential for blood pressure regulation and heart function. Corin's function is not limited to the heart; it also contributes to pregnancy outcomes by supporting uterine adaptation and affects kidney sodium management.

THERAPEUTIC SIGNIFICANCE:
Given Corin's key role in managing blood pressure and its involvement in Pre-eclampsia/eclampsia 5, targeting this enzyme could offer new avenues for treating hypertensive disorders. Exploring Corin's mechanisms further could unlock novel therapeutic strategies, enhancing maternal and neonatal health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.